Client: Discern Test Client
100 TEST
New York, TX 10101
UNITED STATES

Physician: TEST, TEST

Patient: ARUPTEST, LUPUS 1

DOB	1/1/1951
Sex:	Female
Patient Identifiers:	635923
Visit Number (FIN):	661196
Collection Date:	12/4/2023 14:22

Lupus Anticoagulant Reflex Panel

ARUP test code 3017009

Prothrombin Time (PT)	11.0 s L	(Ref Interval: 12.0-15.5)
PTT-LA Ratio	1.20	(Ref Interval: <=1.20)
dRVVT Screen Ratio	1.20	(Ref Interval: <=1.20)
Anti-Xa Qualitative Interpretation	Not Performed	(Ref Interval: Not Present)
Thrombin Time (TT)	Not Performed s	(Ref Interval: <=19.5)
Anticoagulant Medication Neutralization	Not Performed	(Ref Interval: Not Performed)
Neutralized PTT-LA Ratio	Not Performed	(Ref Interval: <=1.20)
Neutralized dRVVT Screen Ratio	Not Performed	(Ref Interval: <=1.20)
dRVVT 1:1 Mix Ratio	Not Performed	(Ref Interval: <=1.20)
dRVVT Confirmation Ratio	Not Performed	(Ref Interval: <=1.20)
Hexagonal Phospholipid Confirmation	Not Performed s	(Ref Interval: <=7.9)
Lupus Anticoagulant, Interpretation	See Note	

Lupus anticoagulant not detected.

This panel did not detect evidence for heparin, direct thrombin inhibitors, or direct Xa inhibitors and drug neutralization was not performed.

Lupus anticoagulant antibodies are heterogeneous and antibody titers fluctuate over time. Laboratory tests used to identify lupus anticoagulant demonstrate variable sensitivity. Testing is best performed when the patient is not acutely ill and not anticoagulated. If there is strong clinical suspicion for antiphospholipid antibody syndrome (APS), consider testing for cardiolipin and beta-2 glycoprotein 1 antibodies (IgG and IgM) if this testing has not already been performed.

INTERPRETIVE INFORMATION: Lupus Anticoagulant Reflex Panel

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or

approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Prothrombin Time (PT)	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 8:59:00 AM
PTT-LA Ratio	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 8:59:00 AM
dRVVT Screen Ratio	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 8:59:00 AM
Anti-Xa Qualitative Interpretation	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM
Thrombin Time (TT)	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM
Anticoagulant Medication Neutralization	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM
Neutralized PTT-LA Ratio	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM
Neutralized dRVVT Screen Ratio	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM
dRVVT 1:1 Mix Ratio	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM
dRVVT Confirmation Ratio	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM
Hexagonal Phospholipid Confirmation	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM
Lupus Anticoagulant, Interpretation	23-338-116965	12/4/2023 2:22:00 PM	12/4/2023 2:29:21 PM	12/5/2023 9:00:00 AM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical